Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GH Research PLCGHRS · Entity 4545 | Director | August 11, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GH Research PLC
Report date August 11, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2033-08-11 | Direct | 2,202 |
Reported balance
After 2026-08-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-11 · Grant · Acquired 2,202 · Balance 2,202 F1: The share options are immediately fully vested, but are not exercisable until August 11, 2028. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2033-08-11 | Direct | 100,000 |
Reported balance
After 2026-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-11 · Grant · Acquired 100,000 · Balance 100,000 F2: The share options vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The share options are immediately fully vested, but are not exercisable until August 11, 2028.
F2: The share options vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 13, 2026 20:41 UTC | GH Research PLC GHRS · Entity 4545 | GrantShare Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032843 · form4.xml · derivative · entry 2 Forer Michael · CIK 0002126827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2033-08-11 F2 · derivative.exercise_date: The share options vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:41 UTC | GH Research PLC GHRS · Entity 4545 | GrantShare Options (Right to Buy) · Derivative | 2,202 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001140361-26-032843 · form4.xml · derivative · entry 1 Forer Michael · CIK 0002126827 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,202 Underlying: Ordinary Shares · 2,202 shares Expires 2033-08-11 F1 · derivative.exercise_date: The share options are immediately fully vested, but are not exercisable until August 11, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.